• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

TNF PHARMACEUTICALS, INC.

Notes

No. Proposition For Against Abstain
1

DIRECTOR Mitchell Glass, M.D.

2

DIRECTOR Christopher C Schreiber

3

DIRECTOR Joshua Silverman

4

DIRECTOR Jude Uzonwanne

5

DIRECTOR Bill J. White

6

DIRECTOR Stephen Friscia

7

To ratify the appointment of Stephano Slack LLC as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2025.

8

To approve an amendment to the Companys Certificate of Incorporation, as amended, to effect, at the discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Companys stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of the Companys Common Stock, at a ratio in the range of 1-for-25 to 1-for-100, with such ratio to be determined by the Board in its discretion and included in a public announcement.

9

To approve an amendment to the Companys Certificate of Incorporation, as amended, to increase the number of the Companys authorized shares of Common Stock from 250,000,000 shares to 1,250,000,000 shares and to make a corresponding change to the number of authorized shares of capital stock.

10

To adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the foregoing proposals.